Zyrtec is one of the most common allergy medications in the country, and it comes in more than one formula. That matters for drug testing, because "Zyrtec" on a store shelf can mean plain cetirizine or it can mean cetirizine combined with the decongestant pseudoephedrine. Those two products behave very differently in front of a standard urine immunoassay. This article separates the two, explains what the research actually supports, and walks through what happens after a screen comes back non negative.
Two products share one brand name
Regular Zyrtec Allergy tablets and liquid gels contain a single active ingredient, cetirizine hydrochloride, a second generation antihistamine. The labeling for that product is on file with the National Library of Medicine and lists no other active drug. You can read the current Zyrtec Allergy tablet labeling on DailyMed to confirm the formula.
Zyrtec-D Allergy and Congestion is a different product. It pairs cetirizine with pseudoephedrine hydrochloride, a nasal decongestant, in an extended release tablet. The Zyrtec-D labeling on DailyMed shows both actives and the dosing split. The distinction is the whole answer to this question. Cetirizine alone is not a known problem for standard panels. Pseudoephedrine is.
How an immunoassay screen can be fooled
A urine drug screen immunoassay does not identify a drug molecule by name. It measures whether a compound in the sample binds to an antibody built to recognize a target analyte's general shape. If another molecule shares enough of that shape, the antibody can bind it too, and the screen reads non negative even though the target drug itself is absent. This is cross reactivity, and it is a known, accepted limitation of screening immunoassays, which is exactly why federal workplace testing rules separate an initial screen from a confirmatory test. The federal cutoff concentrations and testing structure for amphetamines and other classes are set out in the Mandatory Guidelines for Federal Workplace Drug Testing Programs.
Why second generation antihistamines behave differently
Antihistamines are grouped into generations based largely on how much they cross into the central nervous system and how sedating they are. First generation agents such as diphenhydramine are small, fat soluble molecules that cross freely and bind to a wider range of receptors, which is part of why they show up in cross reactivity literature more often. Cetirizine is a second generation antihistamine, built to be less sedating and more selective for the histamine receptor it targets. That structural difference is the practical reason cetirizine does not carry the same documented interference history as diphenhydramine. It also means cetirizine and an older first generation product should not be assumed to behave the same way on a drug screen just because both are sold as allergy relief.
Cetirizine alone: evidence is limited
Cetirizine is a second generation antihistamine. It is not a controlled substance, and it is not a target analyte on any standard SAMHSA style urine panel. The antihistamine cross reactivity reports that do exist in the literature mostly involve first generation agents, not cetirizine. The clearest documented example is diphenhydramine, the active ingredient in some older allergy and sleep aid products, which has been shown in laboratory testing to cross react with methadone and, in some retrospective screening data, with PCP immunoassays. A study on rapid urine screens found measurable diphenhydramine and methadone cross reactivity at clinically relevant concentrations. Cetirizine has a different chemical structure than diphenhydramine, and published reports specific to cetirizine causing a false positive on a standard immunoassay panel are limited. Say that plainly rather than guessing: the evidence for plain cetirizine triggering a false positive is thin, and employers and testers should not assume it behaves like older antihistamines.
Zyrtec-D and the pseudoephedrine problem
Pseudoephedrine is the part of Zyrtec-D that actually has a documented interference history. Pseudoephedrine shares a phenethylamine type backbone with amphetamine and methamphetamine, the same general shape that amphetamine immunoassay antibodies are built to catch. A comparative laboratory study measured ephedrine, pseudoephedrine and phenylpropanolamine concentrations in human urine and tested them against two different amphetamine screening platforms, finding that the two assays did not have the same specificity for these decongestants. That research is published as an evaluation of DRI and Abuscreen amphetamine immunoassay specificity against ephedrine, pseudoephedrine and phenylpropanolamine. In plain terms, a person taking Zyrtec-D as directed can produce a urine sample that screens presumptive positive on an amphetamine or methamphetamine immunoassay, depending on which assay the lab uses and how much pseudoephedrine is in the sample at the time of collection.
| Product | Active ingredients | Screening relevance |
|---|---|---|
| Zyrtec Allergy (tablet, liquid gel, chewable) | Cetirizine hydrochloride only | Not a target analyte on standard panels; documented cross reactivity reports are limited |
| Zyrtec-D Allergy and Congestion | Cetirizine hydrochloride plus pseudoephedrine hydrochloride | Pseudoephedrine has documented cross reactivity on some amphetamine and methamphetamine immunoassays |
| Diphenhydramine products (first generation antihistamine, not Zyrtec) | Diphenhydramine | Documented cross reactivity with methadone and, in some data, PCP screens |
Screening versus confirmation: why one non negative result is not the final word
A non negative immunoassay screen is a preliminary result, not a diagnosis of drug use. Federal workplace testing programs require that any non negative screen be sent for confirmatory testing by gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC-MS/MS). Confirmation testing identifies and quantifies the exact molecule present rather than relying on antibody shape matching, so it can distinguish pseudoephedrine from methamphetamine directly. A published case report involving a different decongestant class medication, atomoxetine, illustrates the same principle: an initial amphetamine immunoassay screen was positive, but the confirmatory GC-MS test returned negative for amphetamine and methamphetamine, overturning the screening result. That two step structure, a sensitive but nonspecific screen followed by a specific confirmation, is the entire reason confirmation testing exists.
What happens at the medical review officer step
In a regulated or employer program that uses a medical review officer, any non negative confirmed result is reviewed by the MRO before it is reported to the employer as positive. The MRO contacts the employee, asks about current medications, and can request documentation such as a pharmacy receipt or a prescription label. The verification interview and the MRO's authority to request supporting documentation are described in the Department of Transportation testing procedures at 49 CFR Part 40. If someone is taking Zyrtec-D, the packaging and any pharmacy receipt are the documentation to keep and bring to that conversation. The MRO's job is to determine whether there is a legitimate medical explanation for a confirmed result, not to make a legal finding, and the final call on how a verified result is handled still belongs to the employer's policy and any applicable law.
Documentation matters on both sides of this conversation. An employee who takes Zyrtec-D should keep the box or a pharmacy printout rather than relying on memory, since the MRO process runs on verifiable records, not a verbal claim. A collection site or employer should keep a clear chain of custody form and a record of which screening platform and cutoff were used, since different immunoassay products do not all cross react with pseudoephedrine to the same degree. That detail can matter if a result is ever questioned later in the review process.
What this means for testers and employers
A person using plain Zyrtec should not expect it to affect a standard urine panel, based on the available evidence. A person using Zyrtec-D should be aware that the pseudoephedrine component has a documented, published history of amphetamine immunoassay cross reactivity and should be prepared to disclose that medication if a screen comes back non negative. Employers and collection sites that want built in confirmation on borderline results should look at panels and drug test cups designed to work inside a documented two step screen and confirm process, since a program that pairs an initial screen with laboratory confirmation and MRO review is the setup that actually resolves cases like this. For a closer look at how pseudoephedrine behaves specifically against methamphetamine panels, see this site's post on pseudoephedrine and meth false positives. For how other antihistamines compare, see the post on hydroxyzine and standard panels.
Frequently asked questions
Does regular Zyrtec cause a false positive drug test?
Plain Zyrtec contains only cetirizine, which is not a target analyte on standard urine panels. Published cross reactivity reports involving antihistamines mostly concern older, first generation agents, not cetirizine, so the evidence for cetirizine alone causing a false positive is limited.
Does Zyrtec-D cause a false positive drug test?
Zyrtec-D contains pseudoephedrine in addition to cetirizine, and pseudoephedrine has documented cross reactivity on some amphetamine and methamphetamine immunoassay screens. A person taking Zyrtec-D as directed can screen presumptive positive on certain platforms.
Can a lab tell the difference between pseudoephedrine and methamphetamine?
Yes. Confirmatory testing by GC/MS or LC-MS/MS identifies and measures the specific molecule present, which distinguishes pseudoephedrine from amphetamine and methamphetamine. The screening immunoassay alone cannot reliably make that distinction.
What should someone taking Zyrtec-D tell the medical review officer?
They should disclose the medication by name, including the fact that it is the "D" extended release formula, and provide documentation such as the product packaging or a pharmacy receipt if the MRO requests it during the verification interview.
Does cetirizine show up as a specific drug on a 10 panel screen?
No. Cetirizine is not one of the analytes a standard SAMHSA style panel is built to detect, and it is not a controlled substance.
Should an employer assume every non negative screen on amphetamines means illegal drug use?
No. A non negative screen is preliminary. Confirmation testing and medical review officer verification exist specifically to sort out legitimate explanations, including common over the counter decongestants, before any result is reported as verified positive.
This article is general information about drug testing science and procedure, not medical or legal advice. Anyone with questions about a specific medication or a specific test result should talk to a licensed clinician, a medical review officer, or qualified counsel.
